|
[Related PubMed/MEDLINE]
Total Number of Papers: 34
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: MK |
| Long Form |
: montelukast |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2021 |
Leukotriene D4 Upregulates Oxidized Low-Density Lipoprotein Receptor 1 and CD36 to Enhance Oxidized LDL Uptake and Phagocytosis in Macrophages Through Cysteinyl Leukotriene Receptor 1. |
LTD4, oxLDL |
| 2 |
2021 |
Montelukast and Coronavirus Disease 2019: A Scoping Review. |
COVID-19, SARS-CoV-2 |
| 3 |
2020 |
Montelukast improves bronchopulmonary dysplasia by inhibiting epithelial‑mesenchymal transition via inactivating the TGF‑beta1/Smads signaling pathway. |
BPD, Col I, LW/BW, MLI, MMP, RAC, TGF |
| 4 |
2019 |
Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. |
DMARDs, FDA, HCQ, HPTLC, MTX, QbD, Rf, SSZ |
| 5 |
2018 |
Effects of anti-allergic drugs on T cell-mediated nasal hyperresponsiveness in a murine model of allergic rhinitis. |
AR, CHL, DEX, NALF, NALT, NHR |
| 6 |
2018 |
Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: Possible role of its antioxidant, anti-inflammatory and antiapoptotic effects. |
p38 MAPK, PD, TH |
| 7 |
2017 |
Resveratrol and Montelukast Alleviate Paraquat-Induced Hepatic Injury in Mice: Modulation of Oxidative Stress, Inflammation, and Apoptosis. |
PQ, RES |
| 8 |
2016 |
Chemical Genomics Identifies the PERK-Mediated Unfolded Protein Stress Response as a Cellular Target for Influenza Virus Inhibition. |
--- |
| 9 |
2016 |
Development of an enantioselective capillary electrophoretic method for the simultaneous determination of montelukast enantiomeric and diastereoisomeric forms and its main degradation product. |
--- |
| 10 |
2016 |
Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis. |
DESs, HCAECs, HCASMCs, LTs, PCI |
| 11 |
2014 |
Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability. |
DMSO, ISI, ISM, NMP, PLGA |
| 12 |
2014 |
HPTLC method for direct determination of gemifloxacin mesylate in human plasma. |
GFX, HPTLC |
| 13 |
2014 |
Influence of montelukast on cisplatin-induced experimental acute renal failure. |
ARF, CIS |
| 14 |
2013 |
Protective effect of high-dose montelukast on salbutamol-induced homologous desensitisation in airway smooth muscle. |
BSMC, PDE |
| 15 |
2013 |
Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney. |
GEN, MDA, NO |
| 16 |
2013 |
Restoration of the normal Clara cell phenotype after chronic allergic inflammation. |
AB/PAS, BUD |
| 17 |
2012 |
Montelukast inhibits leukotriene stimulation of human dendritic cells in vitro. |
moDCs |
| 18 |
2010 |
Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus. |
AHR, CysLT, RSV |
| 19 |
2010 |
Montelukast prevents vascular endothelial dysfunction from internal combustion exhaust inhalation during exercise. |
FMD, LT, PL, PM |
| 20 |
2010 |
Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. |
E-CM, FBS, NM |
| 21 |
2010 |
Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. |
SLIT |
| 22 |
2009 |
[Effects of leukotriene receptor antagonists on vascular endothelial growth factor and its receptors in a sensitized rat model]. |
ELISA, VEGF |
| 23 |
2009 |
[Effects of montelukast and BCG-PSN on the expression of STAT5b mRNA and IL-4 mRNA in blood mononuclearcells of rats with asthma]. |
BCG-PSN, EOS, IFN-gamma, IL-4, OVA, STAT5b |
| 24 |
2008 |
Fluticasone or montelukast for preschool children with asthma-like symptoms: Randomized controlled trial. |
FOT, FP |
| 25 |
2007 |
Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. |
CysLTs, GVHD, SCT |
| 26 |
2006 |
The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model. |
CysLT1, OVA |
| 27 |
2004 |
Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist montelukast and methylprednisolone. |
CysLT, LAR, MP, OVA |
| 28 |
2004 |
[Effect of montelukast on the apoptosis of lymphocytes in asthmatic rats and its molecular mechanism]. |
DXM, OVA, TUNEL |
| 29 |
2004 |
[The effect of montelukast on airway remodeling and the expression of interleukins and transforming growth factor-beta2 mRNA]. |
BALF, IL-4, OVA, RT-PCR |
| 30 |
2003 |
Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. |
BAL, OVA, Th2 |
| 31 |
2003 |
Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites. |
CysLTs |
| 32 |
2003 |
Protective effect of leukotriene receptor antagonist montelukast on smoking-induced lung injury in Wistar rats. |
CS, LMC, LTR-1AT, LTs, Sva.pa |
| 33 |
2002 |
Leukotriene receptor antagonists (Montelukast) in the treatment of asthma crisis: preliminary results of a double-blind placebo controlled randomized study. |
ER, PL |
| 34 |
1999 |
Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway eosinophilia, and IL-5-expressing cells in Brown Norway rats. |
BAL, CysLT |
|
A Search Service for Abbreviation / Long Form
